Boston, MA -- (SBWIRE) -- 08/13/2014 -- Kazakhstan's expanding pharmaceutical industry will continue to be primarily driven by the demand for gene ric drugs, which currently make up over a third of total sales of the market, as the government makes more progress in its efforts to widen the country's currently limited coverage. The Kazakh government's continued commitment to increasing expenditure on healthcare along with rising local wages will drive growth in the healthcare sector.

However, the lack of trained medical professionals and the inherit difficulties of improving healthcare access and infrastructure across such a large country continues to impede market potential. Despite this, Kazakhstan will still be one of the most attractive pharmaceutical markets in the Central Asian region for multinational drug manufacturers.

View Full Report Details and Table of Contents

Headline Expenditure Projections:

- Pharmaceuticals: KZT273.92bn (US$1.80bn) in 2013 to KZT339.81bn (US$1.87bn) in 2014; up 24.1% in local currency terms and 3.7% in US dollar terms.

- Healthcare: KZT1,541bn (US$10.13bn) in 2013 to KZT1,738bn (US$9.55bn) in 2014; +12.8% in local currency terms and -5.7% in US dollar terms.

Risk/Reward Rating:

Kazakhstan has a RRR score of 48.5 out of 100, making it the 15th most attractive pharmaceutical market in Emerging Europe. Although the Kazakh market is characterised by relatively few market barriers and rapid growth, the potential rewards for the industry are moderated by low per capita spending, an unfavourable rural-urban population split

Key Trends And Developments:

In April, the Kazakh health ministry held a meeting to discuss measures to combat corrupt practices in the country's pharmaceutical sector. The meeting, which was attended by Parliament deputies, heads of healthcare organisations and medical institutions, aimed to address the causes of corruption - one of the ministry's priorities. The participants proposed having one distributor for the procurement of medicines to ensure transparency in drug...

The Kazakhstan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kazakhstan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kazakhstani pharmaceutical and healthcare industry.

Key Benefits:

- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kazakhstan to test other views - a key input for successful budgeting and strategic business planning in the Kazakhstani pharmaceutical and healthcare market.

- Target business opportunities and risks in the Kazakhstani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kazakhstan.

- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage:

BMI Industry View & Industry SWOT:

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary:

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime:

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments:

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts:

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Malaysia Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- United Kingdom Pharmaceuticals & Healthcare Report Q3 2014
- Lithuania Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014